Még nem toboroz
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· 3. fázis· Nationwide Children's Hospital· Forrás
Toboroz
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· 2. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· 3. fázis· Almirall, S.A.· Forrás
Toboroz
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00· 3. fázis· K-Group Beta Inc.· Forrás
Toboroz
Study QEL-005-CLN-01. Phase I/II study of QEL-005 in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
2025-523971-46-00· 1/2. fázis· Quell Therapeutics Limited· Forrás
Toboroz
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· 3. fázis· Incyte Corp.· Forrás
Még nem toboroz
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· 3. fázis· Universitaetsklinikum Schleswig-Holstein AöR· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
NCT07564141· 3. fázis· Genmab· Forrás
Toboroz
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00· 3. fázis· Gilead Sciences Inc.· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· AstraZeneca· Forrás
Toboroz
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
2025-524488-18-00· 2. fázis· Astellas Pharma Global Development Inc.· Forrás
Még nem toboroz
A Study of PRO-203 in Healthy Volunteers and Participants with Systemic Sclerosis
2026-526659-70-00· 1. fázis· Prolium Bioscience Inc.· Forrás
Toboroz
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· 3. fázis· Novartis Pharmaceuticals· Forrás
Még nem toboroz
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· 3. fázis· University of Heidelberg Medical Center· Forrás
Még nem toboroz
First-in-Women Study Evaluating the Safety of Lutetium-177 Radioligand Therapy in Metastatic Triple-Negative Breast Cancer
2025-524027-49-00· 1. fázis· Universitaetsklinikum Aachen AöR· Forrás
Toboroz
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· 3. fázis· Summit Therapeutics Inc.· Forrás
Toboroz
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
2025-522878-36-00· 3. fázis· Celldex Therapeutics Inc.· Forrás
Toboroz
A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
2025-523079-44-00· 3. fázis· Ascendis Pharma Endocrinology Division A/S· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )
2024-519818-31-01· 3. fázis· Genmab A/S· Forrás
Toboroz
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants
2025-521762-99-00· 3. fázis· University Medical Center Hamburg-Eppendorf· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
NCT07371585· 2. fázis· SOLTI Breast Cancer Research Group· Forrás
Toboroz
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
NCT07371468· 1. fázis· GlaxoSmithKline· Forrás
Toboroz
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· 3. fázis· Sanofi· Forrás
Toboroz
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· 3. fázis· AstraZeneca· Forrás
Toboroz
Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
2022-500676-59-00· 2. fázis· GPOH gGmbH· Forrás
Toboroz
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
NCT06722183· 2. fázis· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Forrás
Toboroz
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
NCT07280585· 3. fázis· University of Cologne· Forrás
Toboroz
SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
NCT06804161· 3. fázis· Prof. Dr. med. Ingo Eitel· Forrás
Fut, nem toboroz
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
2025-521349-25-00· 3. fázis· 4d Molecular Therapeutics Inc.· Forrás
Toboroz
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA
2024-512922-27-00· 2. fázis· Klinikum der Universitaet Muenchen AöR· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
NCT07260175· 2. fázis· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Forrás
Toboroz
Effect of TRI-001 in patients with chronic limb threatening ischemia
2024-517765-16-00· 1/2. fázis· Ferring Ventures GmbH· Forrás
Toboroz
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307· 2. fázis· Universität Münster· Forrás
Toboroz
– IKF/AIO-QUINTIS –
A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases
2024-519929-38-00· 2. fázis· Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH· Forrás
Toboroz
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
NCT07197866· 2. fázis· Teva Branded Pharmaceutical Products R&D LLC· Forrás
Fut, nem toboroz
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
NCT07187375· 2. fázis· Neurocrine Switzerland GmbH· Forrás
Toboroz
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Showing 50 of 183.